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Efficacy and safety of lavender 
essential oil (Silexan) capsules 
among patients suffering from 
anxiety disorders: A network  
meta-analysis
Wuan Shuen Yap1, Anton V. Dolzhenko  1,2, Zahraa Jalal3*, Muhammad Abdul Hadi  3 & 
Tahir Mehmood Khan1,4*
A systematic review and network-meta analysis (NMA) were performed to estimate significance 
of the anxiolytic effect of lavender essential oil taken as silexan capsules versus other comparators 
(i.e., placebo/paroxetine/lorazepam). The outcome of interest was Hamilton Anxiety Scale (HAMA). 
Weighted mean differences (WMD) were calculated to estimate the treatment effect at the confidence 
interval of 95%. League tables were generated using treatment effect, for all pairwise comparisons, 
where WMD < 0 favors the column-defining treatment. Five studies were identified with a total of 
524 participants receiving treatment with silexan 80 mg and 121 participants taking silexan 160 mg. 
The NMA results indicated that consumption of silexan 160 mg resulted in higher decline of HAMA 
score [WMD −1.14 (−1.10, 3.39)] in comparison to silexan 80 mg, placebo [−2.20 (−4.64, 0.24)] 
and paroxetine [−1.24 (−5.34, 2.85)]. The effect of silexan 80 mg was observed to be same as that 
of paroxetine. Overall, silexan 160 mg was noticed to be a more efficient treatment giving significant 
decline in HAMA score across other comparators. However, no improvements in HAMA score was 
observed for the group receiving lorazepam 0.5 mg when compared to silexan 160 mg, silexan 80 mg, 
paroxetine 20 mg, and placebo.
Among psychiatric disorders, anxiety disorders are more frequent than others1. The global prevalence of anx-
iety disorders based on the data from 87 studies in 44 countries around the world was estimated to be 7.3%2. 
The frequency of anxiety in the population differs greatly between countries. The lifetime prevalence of anxiety 
disorders in United States was reported to be 28.8%3, 14.5% in Europe4 and 20% in Australia5. Anxiety disor-
ders have a huge economic impact on society affecting mainly working-age population. Thus, the prevalence of 
anxiety disorders in United States for the 18–64 years old population reaches 33.7%6. Anxiety often manifests as 
a symptom of other psychiatric disorders and also frequently precedes their onset7,8. Anxiety disorders are also 
more comorbid than other mental disorders9. Their high comorbidity extended to other psychiatric disorders as 
well as physical illnesses.
Due to chronic nature of anxiety disorders, patients suffer from them for a long time, sometimes decades. 
However, therapeutic interventions, such as pharmacotherapy and psychotherapy and their combination, are 
usually beneficial and improve patient’s quality of life often resulting in complete recovery10,11. The meta-analysis 
estimating efficacy of treatments for anxiety disorders suggested that positive effects of pharmacotherapy 
exceeded those of psychotherapy1. Therefore, pharmacotherapy is often critically important in managing patients 
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with anxiety disorders. However, the chronic character of anxiety disorders and requirements of the long-term 
treatment set very high safety and compliance standards for the medications and bring phytotherapy as a treat-
ment option12.
Phytotherapy has been gaining popularity in the treatment of anxiety13–17 with many GABA-modulating med-
icines of herbal origin undergoing preclinical and clinical investigations18. Particular attention has been paid to 
anxiolytic-like effects of essential oils, among which a lavender essential oil demonstrated the best pharmacolog-
ical profile19–21.
Lavender (Lavandula angustifolia Miller or Lavandula officinalis Chaix) has a long history of traditional use 
and its essential oil was found to possess a wide range of biological effects22,23. Evidence of the effectiveness of 
the lavender essential oil in the pharmacotherapy of mental disorders led to the development of Silexan, which 
is a standardized essential oil of L. angustifolia flowers prepared by steam distillation24. Silexan is approved in 
Germany for the treatment of restlessness related to anxiety and marketed as LASEA®25.
Silexan was found to contain 36.8% of linalool and 34.2% of linalyl acetate26. Other components of the lav-
ender essential oil present in substantial quantities include monoterpene alcohol lavandulol, its ester lavandulyl 
acetate, and bicyclic monoterpenoids borneol, eucalyptol (1,8-cineole) and camphor27,28. Linalool also demon-
strated anxiolytic properties in several animal models29,30 and possessed stress-relieving effect in humans under 
the experimental stress31. Studies on molecular mechanisms of pharmacological effects of lavender essential oil 
revealed that its effect on CNS could be attributed to the inhibition of voltage dependent calcium channels26. 
Unlike some other monoterpenes found in the lavender essential oil, linalool and linalyl acetate significantly 
inhibited voltage dependent calcium channels26. In another study, lavender essential oil was demonstrated to 
possess affinity to the NMDA receptor and SERT28. Binding to NMDA receptor was also observed for major 
constituents of lavender essential oil linalyl acetate and linalool, while only linalool demonstrated significant 
binding to SERT28. Further results of the clinical, randomized, placebo-controlled, double-blind, cross-over study 
on healthy men using positron emission tomography technology suggested that the anxiolytic effect of lavender 
essential oil (given as Silexan) could be attributed to the serotonergic system changes, particularly at the 5-HT1A 
receptor level32.
To date, two reviews have been reported in the literature evaluating the efficacy of Silexan in anxiety- 
disorders33,34. Review by Kasper33 in 2013 was not a systematic review, liable to bias, and the author did not com-
bine results of individual studies using meta-analysis. The systematic review and meta-analysis by Möller et al.34  
estimated the efficacy of Silexan in sub-threshold anxiety disorders and reported significant reduction in anxiety 
as measured by HAMA scale. The present systematic review further builds on our existing knowledge on the 
efficacy of Silexan in the management of anxiety disorders by comparing the efficacy of different strengths of 
lavender oil using a network meta-analysis technique. This is a unique technique and is considered superior to 
meta-analysis when direct multiple comparisons between the intervention and control group do not exist in the 
literature35. In addition, our systematic review has evaluated safety of lavender oil as well.
Methods
A systematic review was performed to identify potential research papers across 8 databases from inception till 
December 14, 2017. The NMA was performed, in accordance with the recommendations made by the Preferred 
Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA)36, to estimate the overall effectiveness of 
lavender versus placebo and other medicinal products in anxiety disorders and its adverse effects.
Population intervention comparator and outcomes. 
•	 Population of interest: Patients with anxiety disorder.
•	 Intervention: Lavender given orally (capsules).
•	 Comparators: Placebo or any other medicinal product.
•	 Outcome: Change in Hamilton Anxiety Scale (HAMA) total score of the patients.
Search strategies. Eight electronic databases including Embase via Ovid, MEDLINE via Ovid, Cochrane, 
PubMed, AMED, PsycINFO, SCOPUS and EBSCOHost using the following search terms: lavender OR lavandula 
OR alhucema OR aspic OR lavandin OR lavender essential oil OR lavender oil OR lavandin oil OR aspic oil OR 
lavender extract OR Silexan OR Lasea OR Kalms Lavender One-A-Day OR CalmAid OR MS 1265 OR linalool 
OR linalyl acetate AND anxiety.
All the relevant papers were identified and imported to an EndNote file to create a combined library. Duplicate 
records were removed, where appropriate. Title and abstracts were screened by two authors independently and 
disagreements were resolved through discussions. Full-texts were downloaded and considered for inclusion based 
on the inclusion/exclusion criteria described below. Also, we manually reviewed the references of the included 
studies to identify other relevant studies. Additional details about the studies identified are shown in Fig. 1.
Study selection. The following criteria were used to further align the search with the specific outcomes of 
interest.
Inclusion criteria. 
•	 All English language studies from inception till December 14, 2017 were considered eligible for inclusion in 
this systematic review.
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•	 Only human experimental studies, which are clinical trials comparing the effect of lavender (as a tea, powder 
or capsule) were considered for potential inclusion in order to assess causal assertions. Comparators consid-
ered appropriate were: a placebo, reference/control group, or any other active regimen, which was compared 
with the lavender formulation given orally.
•	 The main outcome of interest is the change in Hamilton Anxiety Scale (HAMA) total score of the patients.
Exclusion criteria. 
•	 Systematic reviews, all observational studies, letter to the editors, case reports, case series, personal opinion, 
qualitative studies, and reviews/communications focusing on individual experience of the use of lavender 
were excluded.
•	 In addition, any data that are not published, reports, and thesis were excluded.
•	 Experimental studies on animals and studies using lavender for aromatherapy were excluded.
Outcome of interest. 
•	 Primary outcomes: Change in Hamilton Anxiety Scale (HAMA) total score of the patients.
•	 Secondary outcome: Safety and tolerability of lavender preparations as a medicine.
Data extraction. Data were extracted independently by two review authors (WSY, TMK) and in the case 
there was a conflict, a third independent assessor AVD assisted in revalidating the data and resolving the conflict. 
A structured, pilot-tested data collection form was designed to collect data from individual studies. In addition 
to the data related to the outcomes of interest, data on the number of authors, year of publication, study design, 
setting and country where the study took place, sample size, patients’ mean age and gender, and inclusion criteria 
and exclusion criteria were also extracted. The results for the outcome measures included in this review were 
summarized as mean and SD difference from baseline to endpoint in both the intervention and control groups. 
When not reported, the mean and SD difference were calculated provided sufficient data were available.
Figure 1. PRISMA flow diagram.
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Data analysis. The risk of bias was assessed individually for each RCT included in this review using Cochrane 
risk of bias assessment tool37. Two authors (MAH, ZJ) assessed risk of bias independently and disagreements were 
resolved through discussion.
The network meta-analysis (NMA) was performed using STATA version 14®. Random effects model was used 
and weighted mean differences with 95% confidence interval (CI) were calculated for all continuous outcome 
measures to compare the effectiveness of the intervention. P-value less than 0.05 was considered statistically 
significant. Furthermore, in order to generate forest plots for NMA, respective pairwise comparisons for the 
treatment effect were carried. League tables were created using treatment effect calculated based on weighted 
mean difference (MD; 95% CI) for all pairwise comparisons. A league table, a square matrix consisting of all 
pairwise comparison within a meta-analysis, empowers researcher/reader to directly compare the direction and 
magnitude of treatment effect, encouraging easier interpretation of results35. A negative (−) MD indicate decline 
in the score for the HAMA and SAS scales.
Author
Recruitment 
site Design
Study period
Sample size (Intervention/
Control)
Intervention(s) Comparison(s)
Measurement tools
Breakdown
Total 
(for each 
participant) Full analysis set Per-protocol Outcome Compliance
Safety and 
tolerability
Woelk & 
Schlafke 
(2009)35
Germany
General 
practitioner’s 
clinics
Multi-centre, 
double-blind, 
randomised 
phase III 
study
1 week screening 
phase, 6 weeks 
treatment 
phase, 2 weeks 
discontinuation 
phase.
9 weeks 40/37 36/33
80 mg Silexan 
capsule +  
Lorazepam 
placebo once 
daily during 
6-week treatment 
phase, and on 
day 43,45,47,50 
and 53 during the 
discontinuation 
phase.
0.5 mg 
Lorazepam 
capsule +  
Silexan placebo 
once daily 
during 6-week 
treatment 
phase, and on 
day 43,45,47,50 
and 53 
during the 
discontinuation 
phase.
Hamilton 
Anxiety 
Rating Scale 
(HAMA 
total score)
Method was 
not reported
Adverse events 
(AE) reported, 
physical 
and ECG 
examinations, 
vital signs, 
routine 
laboratory 
measurements
Kasper et al. 
(2015)38
Germany
17 general 
and 
psychiatric 
practices
Randomized, 
double-blind 
trial
Single-blind 
screening and 
wash-out phase of 
3–7 days, followed 
by 10 weeks 
treatment phase. 
Post-baseline 
efficacy and safety 
assessments 
performed every 
2 weeks
11 weeks 86/84 73/65
80 mg Silexan 
capsule once 
daily
Placebo 
capsules with 
1/1000 the 
amount of 
lavender oil in 
Silexan capsules 
(to match the 
smell of Silexan 
capsules) once 
daily
Hamilton 
Anxiety 
Rating Scale 
(HAMA 
total score)
Compared 
the number 
of unused 
capsules 
returned by 
the patients to 
the expected 
number 
assuming a 
fully protocol 
compliant 
intake
Adverse events 
(AE) reported 
spontaneously, 
physical 
and ECG 
examinations, 
vital signs, 
routine 
laboratory 
measurements
Kasper, et 
al. (2016)39
Germany
35 
psychiatric 
practices
Double-blind, 
randomized, 
placebo-
controlled, 
parallel-group 
multicentre 
trial
Screening period 
of 3–7 days, 
followed by 10 
weeks treatment 
phase. Efficacy and 
safety assessments 
performed at 1 and 
2 weeks ± 2 days, as 
well as at 4, 7 and 10 
weeks ± 7 days after 
baseline
11 weeks 159/156 141/128
80 mg Silexan 
capsule once 
daily
Placebo 
capsules with 
1/1000 the 
amount of 
lavender oil in 
Silexan capsules 
(to match the 
smell of Silexan 
capsules) once 
daily
Hamilton 
Anxiety 
Rating Scale 
(HAMA 
total score)
Assessed by 
counting 
of returned 
medication
Adverse events 
(AE) reported, 
physical 
and ECG 
examinations, 
vital signs, 
routine 
laboratory 
measurements
Kasper, et 
al. (2014)37
Germany
57 
psychiatric 
and general 
practices
Randomized, 
double-blind, 
double-
dummy, 
multi-centre 
trial with 
four parallel 
groups
Screening and 
wash-out phase 
of 3–7 days, 
followed by 10 
weeks treatment 
phase. Efficacy and 
safety assessments 
performed after 
2, 4, 6, 8 and 10 
weeks. Treatment 
phase is followed 
by 1 week down-
titration phase 
for paroxetine 
withdrawal
12 weeks
121 (Silexan 
160 mg/d)/13 
5 (Silexan 
80 mg/d)/132 
(paroxetine)/135 
(placebo)
103 (Silexan 
160 mg/d)/119 
(Silexan 
80 mg/d)/114 
(paroxetine)/114 
(placebo)
160 mg Silexan 
capsule once 
daily; 80 mg 
Silexan capsule 
once daily.
20 mg 
Paroxetine 
capsule; placebo 
capsule.
Hamilton 
Anxiety 
Rating Scale 
(HAMA 
total score)
Assessed by 
medication 
counting
Adverse events 
(AE) reported 
spontaneously, 
physical 
examinations, 
routine 
laboratory 
measurements. 
Withdrawal 
symptoms 
ascertained by 
administering 
the Physician 
Withdrawal 
Checklist 
(PWC-20) at the 
end of treatment 
phase and down-
titration phase.
Kasper, et 
al. (2010)36
Germany
27 general 
and 
psychiatric 
primary care 
centres
Randomized, 
double-blind, 
placebo 
controlled, 
multi-centre 
trial
Single-blind 
placebo screening 
and wash-out 
phase of 3–7 days, 
followed by 10 
weeks treatment 
phase. Post-baseline 
efficacy and safety 
assessments 
performed every 
2 weeks
12 weeks 104/108 87/90 80 mg Silexan capsule daily
Placebo 
capsules with 
1/1000 the 
amount of 
lavender oil in 
Silexan capsules 
(to match the 
smell of Silexan 
capsules) once 
daily
Hamilton 
Anxiety 
Rating Scale 
(HAMA 
total score)
Method was 
not reported
Adverse events 
(AE) reported, 
physical 
and ECG 
examinations, 
vital signs, 
routine 
laboratory 
measurements
Table 1. Study characteristics.
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Results
Included studies. Of the 982 studies screened, five randomized control trials were included in this review 
(Fig. 1).
Characteristics of the studies and type of interventions. To assess the effect of lavender in treat-
ing anxiety, interventions included in the 5 studies were placebo, 80 mg/d silexan, 160 mg/d silexan, 0.5 mg/d 
lorazepam, and 20 mg/d paroxetine. The study by Woelk & Schalfke38 had a treatment phase of 6 weeks whereas 
the other 4 studies by Kasper et al.39–42 had a treatment phase of 10 weeks. All these studies were conducted in 
Germany. The primary outcome in each study was the change in total score of HAMA. Safety and tolerability 
of the interventions were assessed by the reporting of adverse events that occurred over the course of the study. 
Details on study characteristics are available in Table 1.
Although the recruitment criteria for all 5 studies included participants of both genders and of any ethnic-
ity, less than 31% of participants in each study were male and almost all were Caucasian. Woelk & Schlafke38 
Author Respondents
Sample size Male; n (%) 
Full Analysis 
Set
Age (in years) Ethnic 
composition 
n(%)Screened Randomized
Completed 
study Range Median Mean ± SD
Woelk & 
Schlafke 
(2009)35
Germany
Patients (18–65 years old) with a 
primary diagnosis of generalised anxiety 
disorder (GAD) according to DSM-IV 
(300.02) and outpatient treatment by a 
general practitioner.
78 77 74 18 (23.4) 21–65 N/A N/A N/A
Kasper et al. 
(2015)38
Germany
Male and female patients of any ethnicity 
(18 and 65 years old) with restlessness 
and agitation according to the criteria 
of ICD-10 diagnostic category R45.1, 
Hamilton Anxiety Rating Scale 
(HAMA) of at least 18 points, with 
minimum scores of 2 points for HAMA 
items “Tension” and “Insomnia” and 
Pittsburgh Sleep Quality Index (PSQI) of 
at least 6 points.
179 170 148 48 (28.2)
Silexan 
22–67; 
Placebo 
21–67
Silexan 
49; 
Placebo 
48
N/A
Caucasian 169 
(99.4); Asian 1 
(0.6)
Kasper, et 
al. (2016)39
Germany
Male and female patients of any ethnicity 
(18 and 65 years old) with mixed anxiety 
and depressive disorder (MADD) 
according to the criteria of ICD-10 
criteria and Hamilton Anxiety Rating 
Scale (HAMA) of at least 18 points, with 
minimum scores of 2 points for HAMA 
items “Anxious mood” and “Depressed 
mood”.
362 318 290 97 (30.8) N/A N/A Silexan 47.7 ± 12.6; Placebo 47.9 ± 12.6
Caucasian 316 
(99.4); Asian 1 
(0.3); African 
1 (0.3)
Kasper, et 
al. (2014)37
Germany
Male and female patients of any ethnicity 
(18 and 65 years old) with generalized 
anxiety disorder (GAD) according 
to DSM-IV-TR and ICD-10 (F41.1), 
Hamilton Anxiety Rating Scale (HAMA) 
of at least 18 points, with minimum 
scores of 2 points for HAMA items 
“Anxious mood” and “Tension”, HAMA 
subscore for psychic anxiety of less than 
21 points and Covi Anxiety Scale total 
score of at least 9 points
616 539 450 138 (26.4) N/A N/A
Silexan 160 mg/d 
47.1 ± 11.8; Silexan 
80 mg/d 45.7 ± 11.5; 
Paroxetine 45.8 ± 12.4; 
Placebo 44.6 ± 12.3
Caucasian 537 
(99.6); Others 
(0.4)
Kasper, et 
al. (2010)36
Germany
Male and female outpatients of any 
ethnicity (18 and 65 years old) suffering 
from an anxiety disorder according to 
DSM-IV or ICD-10 F41.9, Hamilton 
Anxiety Rating Scale (HAMA) of at least 
18 points, with minimum scores of 2 
points for HAMA items “Anxious mood” 
and “Insomnia” and Pittsburgh Sleep 
Quality Index (PSQI) of at least 5 points.
228 216 187 43 (20.2) N/A N/A Silexan 45.6 ± 11.4; Placebo 46.6 ± 11.3 N/A
Table 2. Participant Characteristics.
Figure 2. Summary of risk of bias.
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conducted a multi-center, double-blind, randomised phase III study assessing the comparative effect of 80 mg 
silexan daily versus 0.5 mg lorazepam daily on a sample size of 78 participants with 23.4% being male. In this 
study, 40 participants received silexan 80 mg. Kasper et al.39 investigated the effect of 80 mg silexan daily against 
placebo in a randomized, double-blind, multi-center trial with 20.2% of its 228 participants being male. In this 
study, 104 participants received treatment with silexan 80 mg.
Following that, Kasper et al.40 conducted a randomized, double-blind, double-dummy, multi-centre trial with 
four parallel groups receiving 160 mg silexan daily (121 patients), 80 mg silexan daily (135 patients), 20 mg par-
oxetine daily, and placebo with 26.4% of male in the sample size of 616 participants. Subsequently, Kasper et al. 
in 201541 investigated the effect of 80 mg silexan daily and used placebo for the reference group. The study design 
was a randomized, double-blind trial with 28.2% of the study’s 179 participants being male38. In this study, 86 
participants were assigned to the silexan 80 mg group. The following year, Kasper et al. published another paper 
to again investigate the effect of 80 mg silexan daily compared to placebo42. In this double-blind, randomized, 
Figure 3. Risk of bias among studies.
Figure 4. Network Plot.
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parallel-group multi-centre trial, the sample size was 362 participants and 30.8% of them were male. The silexan 
80 mg group consisted of 159 participants42. Further details on participant characteristics are shown in Table 2.
Risk of bias. In general, the overall risk of bias was low for most of the domains for the included studies 
(Figs. 2 and 3). In particular, risk was low for selection bias, performance bias and detection bias for all the stud-
ies. One of the studies has unclear risk of bias for allocation concealment (Figs. 2 and 3). In other biases, studies 
were deemed to be high risk of bias as they were funded by the manufacturer.
Effect on HAMA score: Primary outcome. To estimate the effect of all interventions on HAMA, five 
studies were included and a NMA was performed to compare and contrast the effect on the HAMA scale. The net-
work plots demonstrate the organization of all available evidences. The width of the lines represents the number 
of trials and the size of node represents the sample size (Fig. 4).
Overall analysis. Outcome of interventions versus placebo at HAMA scale. Multivariate analysis was per-
formed to estimate the effect of all the active treatments silexan 160 mg, silexan 80 mg, lorazepam 0.5 mg, and 
paroxetine 20 mg versus placebo as the reference arm. Results have revealed that effect of placebo was not supe-
rior in comparison to silexan. Overall, silexan 160 mg −4.963 [−7.167–−2.759], p ≤ 0.001, I2 = 0.00%, Tau2 = 0), 
and silexan 80 mg −3.820 [−5.261–−2.380], p ≤ 0.001, I2 = 0.00%, Tau2 = 0), were noticed to have a significantly 
higher decline in HAMA score in comparison to placebo. Detailed comparison of all treatment with reference 
arm is shown in Table 3.
Furthermore, a pairwise analysis was carried out to estimate the comparative effect of all the treatments ver-
sus placebo and other interventions. Using the pairwise comparison, a league table was generated to present 
all possible pairwise comparisons between any two of the five treatments (Fig. 5). Treatment effect, that is, the 
weighted mean difference of each pairwise comparison was calculated and reported along with the 95% CI. It 
was revealed that lorazepam 0.5 mg had no positive effect and did not cause a decline in HAMA score. The treat-
ment with silexan 160 mg was found to be effective in comparison to placebo, paroxetine 20 mg, and lorazepam 
0.5 mg. Overall, the effect of silexan 160 mg [−1.14 (−1.10, 3.39)], assessed on the basis of declining HAMA 
score, was superior in comparison to silexan 80 mg. In addition, the effect of silexan 80 mg [−1.06 (−3.32,1.21)] 
was observed to be slightly better than that of placebo. The decline in HAMA score was higher for silexan 160 mg 
in comparison to placebo and paroxetine 20 mg. Overall, all interventions including placebo were observed to be 
more effective in declining HAMA score compared to lorazepam 0.5 mg. Details are described in Table 4.
Safety of silexan. In the analyzed 5 studies, adverse events, attributable to silexan use, consisted mainly of gastro-
intestinal problems such as nausea, eructation or breath odour, and diarrhea. A number of patients also reported 
having headaches in the 2015 study by Kasper et al.41 Nevertheless, the number of patients that experienced these 
mild adverse events comprised of a small percentage of the sample size. No serious adverse event was found to be 
linked to the use of silexan.
VS Placebo
Weighted mean 
difference CI 95% Std. Err Z p
Lorazepam 0.5 mg −3.720 [−7.435–0.005] 1.895 −1.96 0.050
Paroxetine 20 mg −2.763 [−4.993–0.533] 1.137 −2.43 0.015
Silexan 160 mg −4.963 [−7.167–2.759] 1.124 −4.41 <0.001
Silexan 80 mg −3.820 [−5.261–2.380] 0.735 −5.20 <0.001
Table 3. Weighted mean difference of interventions versus placebo. I2 = 0.00%, Tau2 = 0.
Figure 5. Pairwise comparison of all treatments.
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Fatigue is a known side effect of lorazepam. In the study conducted by Woelk & Schlafke38, 16.2% of patients 
receiving treatment with lorazepam had fatigue whereas none in the silexan group experienced fatigue. However, 
10.0% in the silexan group had nausea whereas only 2.7% had nausea in the lorazepam group.
The actual number and type of total adverse events experienced by the participants in the study conducted 
by Kasper et al.36,37 were not reported in details. Nonetheless, it was noted by Kasper et al.37 that the participants 
receiving treatment with silexan experienced a 3% increase in risk of gastrointestinal problems compared to those 
in the placebo group. Further details on adverse events reported in the studies can be found in Table 5.
Discussion
To date, perhaps it is the first NMA estimating the effect of oral dosage form of lavender i.e. silexan in com-
parison to placebo, paroxetine and lorazepam on the anxiety score at the HAMA scale. Systematic reviews and 
meta-analysis have proven to be an effective tool to estimate the clinical efficacy and safety of herbs, and further 
comparative analysis using network meta-analysis will provide researcher an opportunity to estimate the clinical 
efficacy and safety of a herb versus various treatments or comparators43. Therefore, the current systematic review 
and NMA will serve as a useful tool in analyzing the use of silexan in clinical settings in an effective manner. The 
overall analysis revealed that administration of silexan 160 mg produced a higher decline in HAMA score [WMD 
−1.14 (−1.10, 3.39)] in comparison to silexan 80 mg. The effect of silexan 80 mg was observed to be similar to 
paroxetine 20 mg. Overall, the treatment with silexan 160 mg resulted in more significant decline in the HAMA 
score across all the comparators and therefore can be considered as the most effective anxiolytic intervention 
for the included studies. However, it should be noted that the dose of lorazepam used in the included RCT, and 
subsequently in this NMA, was only 0.5 mg which is the lowest daily dose recommended. Comparative efficacy of 
silexan with higher dose of lorazepam is not known and needs further research.
The lavender in different forms has been used in cosmetic and therapeutic applications for centuries. These 
applications were driven by unique scent of lavender essential oil. This essential oil became popular in aromather-
apy and its therapeutic effectiveness in this form has been assessed clinically in a number of trials. Particularly, 
aromatherapy with lavender essential oil was effective in managing preoperative stress and anxiety in various 
settings significantly decreasing anxiety level compared to placebo44–46. However, similar interventions applied 
after surgery revealed no difference with control group on anxiety level and mental stress47,48.
The aromatherapy with lavender essential oil improved quality of sleep and reduced level of anxiety in patients 
with coronary artery disease49, significantly reduced anxiety in older patients with acute coronary syndrome50 
and myocardial infarction51. Lower indexes for perceived stress and objective stress were observed in the intensive 
care unit patients receiving aromatherapy with lavender essential oil52. The inhaled lavender essential oil helped 
to alleviate anxiety in burn patients53 and postpartum women54.
However, no significant long-term improvements were observed in control of anxiety for patients suffer-
ing from cancer receiving aromatherapy treatment with lavender essential oil55. No significant difference in the 
anxiety level was also observed between cancer patients receiving inhalation with lavender essential oil during 
radiotherapy and the placebo group56. Overall, the aromatherapy with lavender as an anxiolytic agent has not 
been supported by sufficient evidence of therapeutic efficacy57. However, our NMA was based on the systemic 
administration of the lavender essential oil (Silexan) and demonstrated positive evidences for its anxiolytic effect. 
Silexan 80 mg
1.14 (−1.10,3.39) Silexan 160 mg
−1.06 (−3.32,1.21) −2.20 (−4.64,0.24) Placebo
−0.10 (−3.52,3.32) −1.24 (−5.34,2.85) 0.96 (−3.15,5.06) Paroxetine 20 mg
−3.82 (−5.26,−2.38) −4.96 (−7.17, −2.76) −2.76 (−4.99, −0.53) −3.72 (−7.44, −0.01) Lorazepam 0.5 mg
Table 4. League table for the effect of all interventions on HAMA scale.
Author Year
Intervention/
Control
Type of Adverse Event (AE)
Nausea
Eructation/
breath odour Dyspepsia Fatigue Headache Diarrhoea Gastritis
Oral 
discomfort
Naso-
pharyngitis
Woelk & 
Schlafke35 2009
80 mg/d Silexan 4 (10.0%) 3 (7.5%) 2 (5.0%) — — — — — —
0.5 mg/d 
Lorazepam 1 (2.7%) — — 6 (16.2%) — — — — —
Kasper et al.38 2015
80 mg/d Silexan — 6 (7.0%) — — — 1 (1.2%) 1 (1.2%) 1 (1.2%) —
Placebo — 0 — — — — — — —
Kasper et al.39 2016
80 mg/d Silexan 6 (3.8%) 32 (20.0%) — — 5 (3.1%) 3 (1.9%) — — 3 (1.9%)
Placebo 2 (1.3%) 0 — — 11 (7.1%) 7 (4.5%) — — 8 (5.1%)
Kasper et al.36 2010
80 mg/d Silexan — — — — — — — — —
Placebo — — — — — — — — —
Table 5. Side-effects reported among the participant consumed placebo and intervention treatment.
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More detailed studies are required for the conclusion regarding other methods for the administration of lavender 
essential oil, particularly topically or via inhalation.
Strengths and limitations. The exclusion of non-English articles can be one of the limitations of this 
NMA. This was mainly due to a lack of resources to translate articles written in other languages. There is a slight 
possibility that some relevant data from these non-English literature, if combined with the current analysis, might 
change the significance of lavender effects versus other comparators. In addition, all the studies investigating the 
effect of lavender used its essential oil in form of Silexan capsules. These studies were from Germany and the out-
come might be potentially affected by the patients’ genetics. To get more comprehensive analysis and conclusions 
on the effect of lavender and particularly Silexan capsules, similar clinical studies using ethnically more diverse 
populations are required. The lavender preparations like Silexan capsules might have different results on HAMA 
scale in other races from different genetic makeup. Moreover, the current analysis estimated only the overall effect 
of the treatments on HAMA score, the current study was unable to compare the multiple treatments based on the 
decline in symptoms, severity and relapse of anxiety, which was mainly due to variable reporting of the results 
across the selected studied for the NMA.
Overall, the other bias was observed across all the five included studies. However, one of the main strength of 
this NMA is heterogeneity among the one-on-one comparison and pairwise comparison was 0% which reflects 
no inconsistencies among the studies. A number of factors including similarities between the study populations 
across RCTs included in this NMA as all studies were conducted in Germany, similarities in intervention (all in 
the form of Silexan capsules) and duration of follow-up and use of same tool (HAMA) to assess anxiety in all 
included studies could explain low heterogeneity observed in NMA.
Conclusion
Results (through pairwise comparisons) revealed statistically significant effect of silexan 160 mg versus placebo, 
silexan 80 mg and paroxetine 20 mg. In addition, the effect of paroxetine 20 mg was also observed superior than 
placebo and silexan 80 mg. However, silexan consumption has shown some gastrointestinal side effect such as 
nausea, eructation or breath odor and diarrhea, which were tolerated by the patients recruited in the silexan 
arm. There is a need of more methodological strong studies to further investigate the effect of silexan among the 
patients from other regions to get a comprehensive picture about its clinical efficacy and safety.
Data availability
All materials, data and associated protocols are available to readers without restrictions.
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